Pharming Group Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 404

Employees

  • Stock Symbol
  • PHARM

Stock Symbol

  • Investments
  • 9

  • Share Price
  • $1.02
  • (As of Monday Closing)

Pharming Group General Information

Description

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Vondellaan 47
  • 2332 AA Leiden
  • Netherlands
+31 071
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Commercial Services
Biotechnology
Stock Exchange
AMS
Vertical(s)
Corporate Office
  • Vondellaan 47
  • 2332 AA Leiden
  • Netherlands
+31 071

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharming Group Stock Performance

As of 14-Jul-2025, Pharming Group’s stock price is $1.02. Its current market cap is $697M with 684M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.02 $1.01 $0.71 - $1.25 $697M 684M 9.9M -$0.02

Pharming Group Financials Summary

As of 31-Mar-2025, Pharming Group has a trailing 12-month revenue of $321M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 514,898 608,254 718,479 704,305
Revenue 320,708 297,200 245,316 205,622
EBITDA 16,947 7,844 2,758 33,448
Net Income (14,112) (11,841) (10,548) 13,674
Total Assets 403,181 399,985 462,854 425,797
Total Debt 119,143 112,313 171,545 166,694
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharming Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and
Pharmaceuticals
Leiden, Netherlands
404 As of 2024

Amsterdam, Netherlands
 

Daix, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharming Group Competitors (44)

One of Pharming Group’s 44 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
uniQure Formerly VC-backed Amsterdam, Netherlands
Inventiva Pharma Corporation Daix, France
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Achaogen Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 44 competitors. Get the full list »

Pharming Group Patents

Pharming Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3225079-A1 Using c1 esterase inhibitor to treat viral infection-related symptoms Pending 09-Jul-2021
EP-4366761-A1 Using c1 esterase inhibitor to treat viral infection-related symptoms Inactive 09-Jul-2021
US-20240342258-A1 Using c1 esterase inhibitor to treat viral infection-related symptoms Pending 09-Jul-2021
ES-2981341-T3 C1 esterase inhibitor for treating respiratory distress associated with coronavirus infection Active 17-Apr-2020
EP-4135756-B1 C1 esterase inhibitor to treat coronaviral infection-related respiratory distress Active 17-Apr-2020 A61K38/57
To view Pharming Group’s complete patent history, request access »

Pharming Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharming Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Investments & Acquisitions (9)

Pharming Group’s most recent deal was a Merger/Acquisition with Abliva for . The deal was made on 06-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Abliva 06-Mar-2025 Merger/Acquisition Pharmaceuticals
Pharming Group (EU Commercial Rights) 01-Jan-2020 Corporate Asset Purchase Buildings and Property
Novartis (Leniolisib) 13-Aug-2019 Corporate Asset Purchase Buildings and Property
BioConnection 09-Apr-2019 Corporate BPO/Outsource Services
BioConnection 09-Apr-2019 Secondary Transaction - Private BPO/Outsource Services
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Pharming Group ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

25.44 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Pharming Group’s complete esg history, request access »

Pharming Group Exits (1)

Pharming Group’s most recent exit was on 23-Mar-2006 from Dnage. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Dnage 23-Mar-2006 Completed
To view Pharming Group’s complete exits history, request access »

Pharming Group Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Abliva Lund, Sweden 2000

Pharming Group FAQs

  • When was Pharming Group founded?

    Pharming Group was founded in 1988.

  • Where is Pharming Group headquartered?

    Pharming Group is headquartered in Leiden, Netherlands.

  • What is the size of Pharming Group?

    Pharming Group has 404 total employees.

  • What industry is Pharming Group in?

    Pharming Group’s primary industry is Pharmaceuticals.

  • Is Pharming Group a private or public company?

    Pharming Group is a Public company.

  • What is Pharming Group’s stock symbol?

    The ticker symbol for Pharming Group is PHARM.

  • What is the current stock price of Pharming Group?

    As of 14-Jul-2025 the stock price of Pharming Group is $1.02.

  • What is the current market cap of Pharming Group?

    The current market capitalization of Pharming Group is $697M.

  • What is Pharming Group’s current revenue?

    The trailing twelve month revenue for Pharming Group is $321M.

  • Who are Pharming Group’s competitors?

    uniQure, Inventiva Pharma, Adaptimmune Therapeutics, Renova Therapeutics, and Achaogen are some of the 44 competitors of Pharming Group.

  • What is Pharming Group’s annual earnings per share (EPS)?

    Pharming Group’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »